Influenza A and B conserved internal protein epitopes (Influenza conserved epitopes)

Conserved internal protein epitopes of Influenza A and B are highly stable peptide sequences derived from viral proteins such as Nucleoprotein (NP), Matrix protein 1 (M1), and Polymerase Basic protein 1 (PB1) (Source: PubMed, PMID: 30733131). Unlike surface proteins that mutate rapidly, these internal antigens remain consistent across various strains, making them ideal targets for universal influenza vaccines (Source: Nature Communications, 2019). These epitopes are processed by host cells and presented on the cell surface via Major Histocompatibility Complex (MHC) Class I and II molecules. T-cell receptors (TCRs) on CD8+ and CD4+ T cells recognize these complexes, triggering an immune response that clears infected cells and provides long-lasting heterosubtypic immunity (Source: Frontiers in Immunology, 2020). Therapeutic strategies focusing on these epitopes, such as the vaccines M-001 and FLU-v, aim to provide broad-spectrum protection against both seasonal and pandemic influenza (Source: ClinicalTrials.gov). However, the effectiveness of these therapies is often limited by HLA polymorphism, as specific epitopes must match the patient's MHC profile to be recognized (Source: Journal of Virology, 2018). This target represents a shift from traditional antibody-focused vaccines toward cellular immunity-based protection.

Other names

Conserved influenza antigensInternal influenza protein epitopesUniversal influenza vaccine targetsMHC-restricted influenza peptidesT-cell influenza epitopes

Induction of cellular immune responses where T-cell receptors recognize conserved viral peptides presented by Major Histocompatibility Complex (MHC) molecules on the surface of infected cells, leading to cytotoxic T-lymphocyte (CTL) mediated lysis (Source: PubMed, PMID: 29439962).